JO
PYXS icon

John Overdeck’s Pyxis Oncology PYXS Stock Holding History

John Overdeck’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$253K Buy
83,961
+10,661
+15% +$20.4K ﹤0.01% 4634
2026
Q1 		$107K Sell
73,300
-32,228
-31% -$48.6K ﹤0.01% 4381
2025
Q4 		$121K Buy
105,528
+59,027
+127% +$208K ﹤0.01% 3844
2025
Q3 		$103K Buy
+46,501
New +$67K ﹤0.01% 3465
2025
Q1 		– Sell
-17,067
Closed -$26.6K – 3435
2024
Q4 		$26.6K Sell
17,067
-7,515
-31% -$21.7K ﹤0.01% 3088
2024
Q3 		$90.2K Sell
24,582
-71,121
-74% -$249K ﹤0.01% 2912
2024
Q2 		$317K Buy
+95,703
New +$402K ﹤0.01% 2572
2024
Q1 		– Sell
-91,563
Closed -$165K – 3315
2023
Q4 		$165K Sell
91,563
-28,250
-24% -$48.4K ﹤0.01% 2875
2023
Q3 		$238K Buy
119,813
+11,406
+11% +$26.4K ﹤0.01% 2579
2023
Q2 		$278K Buy
+108,407
New +$344K ﹤0.01% 2538
2023
Q1 		– Sell
-35,477
Closed -$47.5K – 3163
2022
Q4 		$47.5K Sell
35,477
-2,200
-6% -$3.3K ﹤0.01% 2597
2022
Q3 		$74K Sell
37,677
-4,619
-11% -$12.1K ﹤0.01% 2270
2022
Q2 		$101K Buy
+42,296
New +$113K ﹤0.01% 2268

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

John Overdeck's PYXS Position: Q2 2026 in Review

John Overdeck increased its Pyxis Oncology (PYXS) stake by 15% in Q2 2026, buying an estimated $20.4K and bringing the position to 83,961 shares worth $253K. The position accounts for ﹤0.01% of the portfolio, ranked #4634.

John Overdeck first reported a position in PYXS in Q2 2022 and has held it in 13 quarters since. The position peaked at $317K in Q2 2024. 76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • John Overdeck held 83,961 shares of Pyxis Oncology worth $253K as of Q2 2026.
  • John Overdeck bought 10,661 Pyxis Oncology shares in Q2 2026, an estimated $20.4K.
  • Pyxis Oncology made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4634 holding.
  • John Overdeck first reported a position in Pyxis Oncology in Q2 2022 and has held it in 13 quarters since.
  • John Overdeck's Pyxis Oncology position peaked at $317K in Q2 2024.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.